secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0000917520-23-000077
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences to acquire Acclarent from Ethicon for $275M cash plus $5M milestone
--------------------------------------------------------------------------------

- Purchase price: $275M in cash at closing, plus $5M regulatory milestone; acquisition of all outstanding shares of Acclarent.
- Acclarent generated ~$110M revenue in 2022 with gross margins in line with Integra's company average.
- Deal expected to close by Q2 2024, subject to HSR clearance, IIA approval, and other customary conditions.
- Acquisition is accretive to Integra's long-range plan and adds ~$1B to CSS total addressable market.
- Acclarent's ENT portfolio (balloon dilation, navigation systems) is adjacent to Integra's neurosurgery business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000077/0000917520-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000077/iart-20231212.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer